Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance

Curr Med Chem. 2022;29(5):837-848. doi: 10.2174/0929867328666210804090644.

Abstract

Chemotherapy is often the primary and most effective anticancer treatment; however, drug resistance remains a major obstacle to it being curative. Recent studies have demonstrated that non-coding RNAs (ncRNAs), especially microRNAs and long non-coding RNAs, are involved in drug resistance of tumor cells in many ways, such as modulation of apoptosis, drug efflux and metabolism, epithelial-to-mesenchymal transition, DNA repair, and cell cycle progression. Exploring the relationships between ncRNAs and drug resistance will not only contribute to our understanding of the mechanisms of drug resistance and provide ncRNA biomarkers of chemoresistance, but will also help realize personalized anticancer treatment regimens. Due to the high cost and low efficiency of biological experimentation, many researchers have opted to use computational methods to identify ncRNA biomarkers associated with drug resistance. In this review, we summarize recent discoveries related to ncRNA-mediated drug resistance and highlight the computational methods and resources available for ncRNA biomarkers involved in chemoresistance.

Keywords: computational method; database; drug resistance; lncRNA; miRNA; ncRNA.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Drug Resistance, Neoplasm / genetics
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • RNA, Long Noncoding* / genetics
  • RNA, Untranslated / genetics
  • RNA, Untranslated / metabolism

Substances

  • Biomarkers
  • MicroRNAs
  • RNA, Long Noncoding
  • RNA, Untranslated